Update: Immunological Strategies for Prostate Cancer

[1]  P. Kantoff,et al.  Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Steinberg,et al.  Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer , 2010, Cancer Immunology, Immunotherapy.

[3]  W. Isaacs,et al.  Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+ , 2009, The Prostate.

[4]  D. McNeel,et al.  Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Madan,et al.  Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer , 2009, Expert opinion on investigational drugs.

[6]  B. Kavanagh,et al.  Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. , 2009, Cancer research.

[7]  J. Weber.  Ipilimumab: controversies in its development, utility and autoimmune adverse events , 2009, Cancer Immunology, Immunotherapy.

[8]  K. Chi,et al.  Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer , 2008, Current opinion in supportive and palliative care.

[9]  C. Higano,et al.  Phase 1/2 dose‐escalation study of a GM‐CSF‐secreting, allogeneic, cellular immunotherapy for metastatic hormone‐refractory prostate cancer , 2008, Cancer.

[10]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Small,et al.  A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer , 2007, Clinical Cancer Research.

[12]  E. Small,et al.  Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. , 2006, Urologic oncology.

[13]  J. Simons,et al.  Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. , 2006, Urologic oncology.

[14]  P. Schellhammer,et al.  Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Jaffee,et al.  Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.

[16]  Debashis Ghosh,et al.  Autoantibody signatures in prostate cancer. , 2005, The New England journal of medicine.

[17]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[18]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[19]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[20]  D. Smith,et al.  A phase 2 study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (HRPC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Manola,et al.  Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Meyerhardt,et al.  Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Clayman.  American Urological Association. Annual Meeting , 2003 .

[24]  J. Buckner,et al.  Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  J. Schlom,et al.  A triad of costimulatory molecules synergize to amplify T-cell activation. , 1999, Cancer research.

[26]  E. Engleman,et al.  Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. , 1997, Journal of immunology.

[27]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.